Glycinorm 80 Tablet contains Gliclazide 80 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control in patients with non-insulin-dependent diabetes. Glycinorm 80 is typically prescribed as an adjunct to diet and exercise when these measures alone are insufficient to achieve adequate blood glucose regulation. The medication aids in reducing fasting and postprandial blood glucose levels, contributing to overall glycemic stability and minimizing the risk of diabetes-related complications. Dosage should be individualized based on patient response and glycemic targets, with careful monitoring to avoid hypoglycemia, a potential adverse effect. Contraindications include type 1 diabetes, diabetic ketoacidosis, and hypersensitivity to sulfonylureas. Caution is advised in patients with hepatic or renal impairment, and during pregnancy or lactation. Regular monitoring of blood glucose and periodic assessment of renal and hepatic function is recommended during therapy. Glycinorm 80 should be used under medical supervision, with patient education on recognizing symptoms of hypoglycemia and appropriate management strategies.